2/27
09:47 am
nuvl
Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.
2/26
06:55 am
nuvl
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
06:30 am
nuvl
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
2/20
01:26 pm
nuvl
Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) [Seeking Alpha]
Low
Report
Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) [Seeking Alpha]
2/9
08:37 am
nuvl
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing [Yahoo! Finance]
Low
Report
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing [Yahoo! Finance]
2/5
06:30 am
nuvl
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
1/12
06:46 am
nuvl
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones [Yahoo! Finance]
Medium
Report
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones [Yahoo! Finance]
1/12
06:30 am
nuvl
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Medium
Report
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
12/24
12:37 am
nuvl
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
Low
Report
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
12/22
06:43 am
nuvl
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/22
06:30 am
nuvl
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/19
11:38 am
nuvl
Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.
12/17
01:07 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/16
07:22 am
nuvl
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million [Yahoo! Finance]
Low
Report
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million [Yahoo! Finance]
12/10
04:01 pm
nuvl
Nuvalent Appoints Ron Squarer to Board of Directors
Low
Report
Nuvalent Appoints Ron Squarer to Board of Directors
12/9
12:27 am
nuvl
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects [Yahoo! Finance]
Low
Report
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects [Yahoo! Finance]